BioNTech Results Presentation Deck

Strong Performance in the Third Quarter of 2021 Corporate Updates Reported Q3 total revenues of €6.1 bn Acquisition of PhagoMed: Expansion into new class of precision antibacterials Third Quarter 2021 Highlights 9 Continued Pipeline Advancement RANDOMIZED PHASE 2 TRIAL STARTS iNeST: autogene cevumeran (BNT 122/ RO7198457; adjuvant treatment of ctDNA+, resected Stage II/III colorectal cancer) FIRST-IN-HUMAN PHASE 1 TRIAL STARTS mRNA vaccine: BNT 161 (influenza) COVID-19 Vaccine* Delivered >2 bn doses to more than 152 countries and territories worldwide, including low- and middle-income countries* ● ● ● Expect to deliver up to 2.5 bn doses in 2021 U.S. government purchased an additional 50 m pediatric doses (5 to <12 years of age) CPI R/R, checkpoint inhibitor resistant or refractory "As of November 2, 2021: includes doses shipped by collaboration partner Pfizer SITC PRESENTATIONS Safety and preliminary efficacy signals for 6 oncology programs across 3 therapeutic platforms. BNT111 GRANTED FDA ORPHAN DESIGNATION IN CPI R/R MELANOMA BLA APPROVAL IN U.S. BOOSTER DOSE Approved in EU for individuals ≥18 years of age Authorized for ≥65 and high-risk populations in U.S. LABEL EXTENSION ● ● ● Clinical data for children aged 5 to <12 submitted to regulators globally EUA approval in the U.S. for children 5 to <12 BIONTECH

View entire presentation